Recent Updates
Recently added Catalysts
ZLAB

Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study – Zai Lab Limited

Wednesday, April 13, 2022 1 min read
Key Takeaway: Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study – Zai Lab Limited

Full Press Release Details

Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study – Zai Lab Limited.
Tags: ZLAB Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Apr 13, 2022